# IKZF2

## Overview
IKZF2 is a gene that encodes the protein IKAROS family zinc finger 2, commonly referred to as HELIOS. This protein is a transcription factor characterized by its KrÃ¼ppel-like zinc-finger domains, which are essential for DNA binding and protein-protein interactions. HELIOS plays a crucial role in the immune system, particularly in the regulation of T cell development and function. It is highly expressed in regulatory T cells and is involved in maintaining immune tolerance and modulating immune responses. Mutations in the IKZF2 gene can lead to various immune-related disorders, highlighting its significance in immune regulation and disease (Lu2023A; HetemÃ¤ki2021Loss-of-function).

## Structure
The molecular structure of the IKZF2 protein, also known as Helios, includes multiple zinc finger domains which are crucial for its function as a transcription factor. These domains facilitate DNA binding and protein-protein interactions essential for transcriptional regulation. Specifically, the protein contains a N-terminal domain responsible for DNA binding and a C-terminal domain that aids in dimerization with other members of the IKAROS family, such as IKAROS and AIOLOS (HetemÃ¤ki2021Loss-of-function).

A notable mutation in the IKZF2 gene results in a truncated Helios protein with impaired function. This mutation introduces a premature stop codon in the sequence coding for the fourth DNA-binding zinc-finger, leading to reduced dimerization capabilities and impaired interactions within the Mi-2/NuRD complex, crucial for DNA modulation and transcription regulation (HetemÃ¤ki2021Loss-of-function).

Additionally, a structural variant in the gene leads to a duplication of zinc fingers 2 and 3, impacting the protein's stability and function, particularly affecting its ability to repress the IL2 promoter (Lu2023A).

The excerpts do not provide detailed information on the primary, secondary, tertiary, or quaternary structures of IKZF2, nor do they discuss prominent folds, common post-translational modifications, or splice variant isoforms in detail.

## Function
IKZF2, also known as HELIOS, encodes a zinc-finger transcription factor that is a member of the IKAROS family, playing a pivotal role in the regulation of gene expression within the immune system. HELIOS functions as both a transcriptional activator and repressor, crucial for DNA binding and protein dimerization due to its KrÃ¼ppel-like zinc-finger domains. It is predominantly active in the immune system, particularly influencing the development and function of T cells. HELIOS is highly expressed in regulatory T cells (Tregs) and effector T cells, especially following TCR-mediated activation (HetemÃ¤ki2021Loss-of-function).

In the context of chromatin remodeling, HELIOS interacts with the Mi-2/NuRD complex, a major transcriptional corepressor complex, which is essential for orchestrating immune responses and maintaining peripheral immune tolerance (HetemÃ¤ki2021Loss-of-function). This interaction also supports the non-inflammatory phenotype of Tregs, potentially through STAT-5 mediated signaling, and plays a role in epigenetically silencing IL-2 production in Tregs (HetemÃ¤ki2021Loss-of-function).

Furthermore, HELIOS is involved in the differentiation and function of mucosal-associated invariant T cells (MAITs) and controls germinal center reactions, which influence the formation and function of T follicular helper cells and germinal center B cells (HetemÃ¤ki2021Loss-of-function). The loss-of-function mutation in IKZF2 leads to a reduction in HELIOS expression, resulting in immune dysregulation and immunodeficiency, characterized by altered T cell immunophenotypes and increased proinflammatory signaling (HetemÃ¤ki2021Loss-of-function).

## Clinical Significance
Mutations in the IKZF2 gene, which encodes the Helios protein, have been linked to a range of immune-related disorders due to its critical role in immune regulation. Loss-of-function mutations in IKZF2 can lead to primary immune regulatory disorders (PIRDs), characterized by a spectrum of immune-mediated pathologies including autoimmunity, lymphoproliferation, malignancy, autoinflammation, and atopy (Lu2023A). Specific clinical manifestations associated with these mutations include combined immunodeficiency (CID), immune thrombocytopenia (ITP), Evan's syndrome, and systemic lupus erythematosus. Additionally, a novel germline heterozygous dominant negative IKZF2 variant has been identified in patients with a syndrome characterized by immunodysregulation, craniofacial anomalies, hearing impairment, athelia, and developmental delay (ICHAD syndrome), highlighting the gene's role in diverse immune and developmental disorders (Lu2023A).

Furthermore, alterations in IKZF2 expression are associated with various hematological malignancies. High expression of IKZF2 in malignant T cells, as observed in cutaneous T cell lymphoma (CTCL), particularly in mycosis fungoides (MF), is correlated with adverse prognosis, including shorter overall survival and progression-free survival. This overexpression is linked to T cell exhaustion and dysfunction, promoting disease progression (Xu2021High). Conversely, a loss-of-function mutation in IKZF2 leads to immunodeficiency characterized by recurrent infections, chronic lymphadenopathy, and dysregulated germinal center reactions, which can potentially lead to the production of autoantibodies (HetemÃ¤ki2021Loss-of-function). These findings underscore the critical role of IKZF2 in maintaining immune homeostasis and its implications in human health and disease.

## Interactions
IKZF2, also known as Helios, is involved in several significant protein-protein interactions that play crucial roles in cellular processes and immune system regulation. In the context of lupus nephritis, IKZF2 forms an associated protein-protein interaction (PPI) network, which has been analyzed to understand its molecular functions and interactions within immune responses (Zhou2022Omics-based). Additionally, IKZF2 interacts with TBX18, a transcription factor, enhancing the repressive activity of TBX18 by potentially forming complexes with other transcriptional regulators such as CHD family members, CBFB, and histone deacetylases (HDACs) (Rivera-Reyes2018Proteomic). This interaction suggests a role in chromatin remodeling and transcriptional regulation during blood cell development. Furthermore, IKZF2 has been shown to bind directly to the T-box domain of TBX18, influencing TBX18's transcriptional activity in a dose-dependent manner, which indicates not only a physical but also a functional interaction impacting transcriptional repression (Rivera-Reyes2018Proteomic). These interactions highlight the multifaceted role of IKZF2 in gene expression regulation and its potential impact on disease mechanisms and developmental processes.


## References


[1. (Zhou2022Omics-based) Mi Zhou, Yuening Kang, Jun Li, Rongxiu Li, and Liangjing Lu. Omics-based integrated analysis identified ikzf2 as a biomarker associated with lupus nephritis. Scientific Reports, June 2022. URL: http://dx.doi.org/10.1038/s41598-022-13336-5, doi:10.1038/s41598-022-13336-5. (2 citations) 10.1038/s41598-022-13336-5](https://doi.org/10.1038/s41598-022-13336-5)

[2. (HetemÃ¤ki2021Loss-of-function) Iivo HetemÃ¤ki, Meri Kaustio, Matias Kinnunen, Nelli HeikkilÃ¤, Salla Keskitalo, Kirsten Nowlan, Simo Miettinen, Joona Sarkkinen, Virpi Glumoff, Noora Andersson, Kaisa Kettunen, Reetta Vanhanen, Katariina Nurmi, Kari K. Eklund, Johannes Dunkel, Mikko I. MÃ¤yrÃ¤npÃ¤Ã¤, Heinrich Schlums, T. Petteri Arstila, Kai Kisand, Yenan T. Bryceson, PÃ¤rt Peterson, Ulla Otava, Jaana SyrjÃ¤nen, Janna Saarela, Markku Varjosalo, and Eliisa KekÃ¤lÃ¤inen. Loss-of-function mutation in ikzf2 leads to immunodeficiency with dysregulated germinal center reactions and reduction of mait cells. Science Immunology, November 2021. URL: http://dx.doi.org/10.1126/sciimmunol.abe3454, doi:10.1126/sciimmunol.abe3454. (41 citations) 10.1126/sciimmunol.abe3454](https://doi.org/10.1126/sciimmunol.abe3454)

[3. (Xu2021High) Bufang Xu, Fengjie Liu, Yumei Gao, Jingru Sun, Yingyi Li, Yuchieh Lin, Xiangjun Liu, Yujie Wen, Shengguo Yi, Jingyang Dang, Ping Tu, and Yang Wang. High expression of ikzf2 in malignant t cells promotes disease progression in cutaneous t cell lymphoma. Acta Dermato-Venereologica, 101(12):adv00613, December 2021. URL: http://dx.doi.org/10.2340/actadv.v101.570, doi:10.2340/actadv.v101.570. (6 citations) 10.2340/actadv.v101.570](https://doi.org/10.2340/actadv.v101.570)

[4. (Lu2023A) A germline heterozygous dominant negativeIKZF2variant causing syndromic primary immune regulatory disorder and ICHAD (0 citations) 10.1101/2023.09.09.23295301](https://doi.org/10.1101/2023.09.09.23295301)

[5. (Rivera-Reyes2018Proteomic) Reginaldo Rivera-Reyes, Marc-Jens Kleppa, and Andreas Kispert. Proteomic analysis identifies transcriptional cofactors and homeobox transcription factors as tbx18 binding proteins. PLOS ONE, 13(8):e0200964, August 2018. URL: http://dx.doi.org/10.1371/journal.pone.0200964, doi:10.1371/journal.pone.0200964. (10 citations) 10.1371/journal.pone.0200964](https://doi.org/10.1371/journal.pone.0200964)